Abstract
Progress in genomic medicine has provided novel insight of susceptibility genes for complex disorders, including psychiatric disorders. These results revealed the fact that the effect size of the “associated” single nucleotide polymorphisms (SNPs) is small, as well as that the variants with large effect size are rare. This indicates that a very large number of subjects will be required to detect significant SNPs or variants.
Taken these into account, the author reviewed the recent findings of psychiatric genomics and introduced the importance of collaborative effort for generating the large “sample size” or “secondary use” of biobank resources (data from genome‐wide association studies, whole exome/genome sequencing analysis) , aiming to establish the personalized medicine.
COI : No potential conflicts of interest were disclosed
